Background: Treatment of large bone defects due to trauma, tumor resection, or congenital abnormalities is challenging. Bone tissue engineering using mesenchymal stem cells (MSCs) represents a promising treatment option. However, the quantity and quality of engineered bone tissue are not sufficient to fill large bone defects. The aim of this study was to determine if the addition of enamel matrix derivative (EMD) improves in vitro chondrogenic priming of MSCs to ultimately improve in vivo MSC mediated endochondral bone formation.
INTRODUCTION
Trauma, tumor resection, or congenital abnormalities can result in large bone defects in the craniomaxillofacial region as well as elsewhere in the body. Treatment options of such defects include the use of autologous or allogenic bone or other substitutes (Arrington et al., 1996; Froum et al., 2001 ). Autologous bone is preferred clinically; however, harvesting of material can result in secondary site morbidity and an increased risk of infection (Arrington et al., 1996) . In addition, tissue availability is limited, increasing the demand for an alternative graft substitute (Meijer et al., 2008) .
Tissue engineering represents a promising alternative treatment option for such defects. Mesenchymal stem cells (MSCs), available from tissues including bone marrow and adipose tissue, are multipotent cells that can be differentiated the osteogenic and chondrogenic lineages (Pittenger et al., 1999) making them an attractive cell source for bone tissue engineered constructs.
Multiple approaches have been taken to improve osteogenic differentiation of MSCs, mimicking the process of intramembranous ossification, including manipulating growth factors, scaffolds, and environmental parameters (e.g., oxygen and pressure) (Salgado et al., 2004) . Unfortunately, because these bone tissues lack vasculature, necrosis, improper nutrient delivery, and inadequate waste removal occur, ultimately resulting in graft failure.
Bone tissue constructs modeled after the process of endochondral ossification (EO) may result in more promising outcomes as the tissue would be better suited to survive the initial avascular implantation site. During EO, cartilage is formed by chondrogenic differentiation of MSCs in vitro. Since chondrocytes reside in an avascular environment, they can survive the initial hypoxic insult following implantation (Coyle et al., 2009) . As the chondrocytes mature, become hypertrophic, and apoptose, blood vessels invade and the cartilage rich matrix is mineralized and serves as a template for future bone development. Several groups have produced promising results on the ability of MSCs to guide bone formation along the process of EO in vivo (Huang et al., 2006; Farrell et al., 2009 Farrell et al., , 2011 Gawlitta et al., 2010; Janicki et al., 2010; Scotti et al., 2010; Thompson et al., 2014) . van der Stok et al. (2014) demonstrated proof of principle in repairing a long bone defect using this approach. However, despite the promise of this approach, the resulting bone is not sufficient to fill large clinically www.frontiersin.org relevant defects, indicating a need to improve current techniques to optimize bone return. Many researchers have investigated combining MSC with clinically relevant compounds to improve in vivo bone formation.
Enamel matrix derivative (EMD) is an extracellular matrix derivative obtained from porcine tooth buds. It contains amelogenin and proteins that belong to the amelogenin family (>90%) (Grandin et al., 2012) . It is sold commercially as Emdogain in a single dose syringe dissolved in propylene glycol alginate. Emdogain is used clinically to stimulate the regeneration of periodontal tissues. Combining EMD with surgical periodontal therapy (surgical therapy of the tissue surrounding or encasing teeth) of deep intrabony defects leads to improvement in clinical parameters compared to surgical therapy alone (Froum et al., 2001) . Studies have shown that EMD stimulates the proliferation and osteogenic differentiation of MSCs (Narukawa et al., 2007a; Jue et al., 2010; Song et al., 2010; Grandin et al., 2012) . However, many groups used only specific proteins that are included in EMD or based their results on cells obtained from animals or cell-lines. The research group of Narukawa found a stimulatory effect of Emdogain on the expression of chondrogenesisrelated transcription factors in chondrogenically primed MSCs. Utilizing a chondrogenic cell line, the group also observed an increase in the amount of glycosaminoglycans (GAGs) formed in the extracellular matrix (Narukawa et al., 2007a,b) . In an additional study, EMD was shown to increase the proliferation of early chondrocytes derived from rats and inhibited maturation. In more mature chondrocytes, EMD enhanced proliferation and no longer inhibited differentiation (Dean et al., 2002) . Due to its clinical relevance and previous evidence indicating an improvement in chondrogenesis, at least on gene expression in a chondrogenic cell line, EMD was hypothesized to improve in vitro chondrogenic priming of human MSCs. These chondrogenically primed human MSCs could be implanted in order become hypertrophic and mineralized leading toward bone formation via EO in vivo. Assuming this to be the case, it was hypothesized that these primed cells would lead to improved bone formation in vivo. The aim of this research was to determine if EMD enhanced chondrogenesis in human MSCs and to determine if EMD improves the quantity and quality of the chondrogenic matrix production. In order to compare with previous research, we also assessed the osteogenic capacity of MSCs in the presence of varying doses of MSCs as well as their adipogenic differentiation capability.
MATERIALS AND METHODS

EMD
Enamel matrix derivative was supplied as a freeze dried preparation by Straumann Company. It was reconstituted in 50 mM acetic acid to 10 mg/mL and further diluted to the working concentrations below in the appropriate culture medium.
MSC ISOLATION
Mesenchymal stem cells were isolated from three human bone marrow samples aspirated from the greater trochanter major from patients undergoing total hip arthroplasty, after informed consent (METC 2004-142) . There were two females (aged 20 and 60) and one male (aged 54). Cells from each donor showed similar growth and differentiation characteristics. Cells were maintained in expansion medium, α-mem (Gibco) containing 10% FCS (Lonza), supplemented with 1 ng/mL FGF2 and 25 µg/mL Ascorbic acid at 37°C and 5% CO 2 as described previously (Leijs et al., 2012) .
ADIPOGENESIS
Mesenchymal stem cells were cultured in 12-well plates at a density of 7.98 × 10 5 cells/well. Cells were cultured for 14 days at 37°C and 5% CO 2 in adipogenic induction medium, DMEM containing 10% FCS, supplemented with 1 µM dexamethasone, 0.2 mM indo-methacin, 0.01 mg/mL insulin, and 0.5 mM 3-isobutyl-l-methyl-xanthine (Sigma). EMD treated samples were cultured in 1, 10, or 100 µg/mL EMD or vehicle alone (0.5 mM acetic acid). Medium was replaced twice a week.
OSTEOGENESIS
Mesenchymal stem cells were cultured in 12-well plates at a density of 1.14 × 10 4 cells per well. Cells were cultured for 15-19 days at 37°C and 5% CO 2 in osteogenic induction medium, high-glucose DMEM (Invitrogen) with addition of 10% FCS, 50 µg/mL gentamycin (Invitrogen), 1.5 µg/mL fungizone (Invitrogen), 10 mM glycerol 2-phosphate (Sigma), 0.1 µM dexamethasone (Sigma), and 0.1 mM ascorbic acid (Sigma). EMD treated samples were cultured in 1, 10, or 100 µg/mL EMD or vehicle. Medium was replaced twice a week. Samples were harvested at the latest point prior to detachment of the cells from the surface of the tissue culture plastic, as occurs during osteogenic differentiation in monolayer. This varied from 15-19 days between donors.
CHONDROGENESIS
Mesenchymal stem cells were cultured for 21 or 35 days in pellets of 2.0 × 10 5 cells in chondrogenic medium, high-glucose DMEM supplemented with 50 µg/mL gentamycin (Invitrogen), 1.5 µg/mL fungizone (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 40 µg/mL proline (Sigma), 1:100v/v insulin-transferrinselenium (ITS; BD Biosciences), 10 ng/mL transforming growth factor β1 (R&D Systems), 25 µg/mL ascorbic acid (Sigma), and 100 nM dexamethasone (Sigma). EMD treated samples were cultured in 1, 10, or 100 µg/mL EMD or vehicle alone. Medium was replaced twice a week.
OIL RED O STAINING
Lipid droplets were stained by Oil Red O. Cells in monolayer were washed in 0.9% NaCl and fixed for 1 h in 4% paraformaldehyde. Cells were stained with Oil Red O (0.3% w/v in distilled water; Sigma) for 10-15 min and washed with distilled water. Cells were mounted with Vectamount.
von KOSSA STAINING
Cells in monolayer were washed in 0.9% NaCl, fixed with 4% formaldehyde for 1 h and stained with von Kossa staining. Cells were incubated in 5% silver nitrate and placed on a light box for 15 min. Excess silver nitrate was washed using distilled water and cells were placed on a light box for another 10 min. Cells were washed in distilled water and counterstained with thionine for 5 min. Cells were dehydrated in 70% (10 s), 96% (30 s), and 100% ethanol (2 min) and mounted with Vectamount. 
SCAFFOLD SEEDING
Collagen-glycosaminoglycan (Collagen-GAG) scaffolds were cut in 8 mm squares, placed in 6-well plates coated with 2% agarose (LE-analytical grade, Promega). Scaffolds were seeded with 5 × 10 5 cells in 150 µL culture medium on one side, incubated for 30 min then overturned and seeded again with the same cell number and volume. After another 30 min, the well was filled with 3 mL of culture medium. Constructs were cultured in chondrogenic medium with the addition or absence of 10 ng/mL transforming growth factor-β 1 (TGF-β1) and/or 100 µg/mL EMD. Samples were cultured at 37°C and 5% CO 2.
GENE EXPRESSION ANALYSIS
RNA was isolated from chondrogenic pellets by homogenizing samples with a Eppendorf-potter in 350 µL RNAbee (Freund Can Company). Adipogenic and osteogenic primed MSCs cultured in monolayers, 2-wells were combined in 300 µL RNAbee. RNA isolation, cDNA synthesis, and measurement of gene expression levels on 8-15 ng cDNA were performed as described before (Verseijden et al., 2009; Leijs et al., 2012) . Primers and probes used for alkaline phosphatase (ALPL), Gamma-carboxyglutamic acid-containing protein (BGLAP), Integrin-binding sialoprotein (IBSP), Collagen type I (COLI), Peroxisome proliferator-activated receptor γ (PPARγ), Fatty acid-binding protein 4 (FABP4), Runt-related transcription factor 2 (RUNX2), Collagen type II (COL II), Collagen type X (COL X), Sex determining region Y-box 9 (SOX 9), and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are represented in Table S1 in Supplementary Material.
GLYCOSAMINOGLYCAN QUANTIFICATION
Pellets and scaffolds were digested in 150 µL papaine digestion solution in combination with 150 µL sodium citrate buffer. GAGs were measured and adjusted to the amount of DNA present in each pellet or scaffold as described before using heparin (Leo Pharmaceutical Products BV), RNAse (Ribonuclease type III-A; Sigma), and ethidium bromide (GibcoBR1) (Clockaerts et al., 2011) .
HISTOLOGICAL PREPARATION
Pellets and scaffolds were fixed in 4% paraformaldehyde for 1 h, embedded in liquid paraffin wax, and cut into 5 µm sections using a microtome (Leica RM2135). Sections were placed onto SuperStar® microscope slides and de-waxed by soaking sequentially in xylene and 100, 96, and 70% ethanol (5 min each).
www.frontiersin.org 
GLYCOSAMINOGLYCAN AND H&E STAINING
Glycoaminoglycan formation was determined by 0.1% safranin O staining and cell morphology was determined utilizing H&E staining. Stainings were performed as described previously (Narcisi et al., 2012; de Vries-van Melle et al., 2013) .
IMMUNOHISTOCHEMICAL STAINING FOR COLLAGEN TYPE II
Antigen retrieval was performed using 0.1% pronase and 1% hyaluronidase. Sections were incubated with 1:100 mouse monoclonal antibody against collagen type II and stained by an ALPL substrate as described before (Narcisi et al., 2012) .
STATISTICS
Data are presented as mean values ±SD. Statistical analysis was carried out using repeated measures ANOVA test followed by Tukey post hoc correction using a statistical software package (Prism 5.00, Graphpad Software). Results were considered statistically significant at p < 0.05.
RESULTS
EMD DOES NOT AFFECT THE OSTEOGENIC DIFFERENTIATION CAPACITY OF HUMAN MSCs
Osteogenic genes ALPL, BGLAP, IBSP, and COL I were analyzed after 15-19 days by real-time PCR. No differences were observed between osteogenic control, vehicle, and the different doses of EMD (p-values respectively 0.1600, 0.2578, 0.6016, and 0.5673; Figure 1 ). Despite inter-donor variability, no differences were observed in the amount of calcium phosphate-nodules formed at the macroscopic level (Figure 2 ). This suggests that EMD had no effect on the osteogenic differentiation of MSCs.
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EMD HAS NO EFFECT ON THE ADIPOGENIC DIFFERENTIATION OF HUMAN MSCs
Adipogenic genes, FABP4 and PPARγ, were investigated for three donors by real-time PCR after 14 days to determine the role of EMD on adipogenesis. Cells cultured in the high dose EMD (100 µg/mL) showed a trend toward inhibition of gene expression compared to vehicle and adipogenic control. However, given the large inter-donor variability, this difference was not statistically significant for FABP4 (p = 0.4835) or PPARγ (p = 0.1063; Figure 3 ). The effects of vehicle and EMD on adipogenic differentiation were also assessed by Oil Red O staining of fat-containing droplets. No cells cultured in the expansion medium (used as a negative control) showed evidence of fat-containing droplets ( Figure 4A) . When MSCs were cultured in all other treatment conditions, cells positively stained in all conditions (Figures 4B-F) . Staining was slightly reduced in the high dose EMD (100 µg/mL) compared to adipogenic control or vehicle across all donors and wells. This suggests, together with the results for FABP4 and PPARγ, a potentially inhibitory effect of EMD on adipogenic differentiation of MSCs at the highest dose. However, this effect was minimal as determined by staining.
EMD DOES NOT AFFECT THE CHONDROGENIC DIFFERENTIATION CAPACITY OF HUMAN MSCs
Chondrogenically primed cell pellets were analyzed by real-time PCR after 21 days for three donors. Four different chondrogenic genes were analyzed; COL II, COL X, SOX 9, and RUNX2 ( Figure 5 ). After treatment with vehicle only or EMD, no statistical significant differences in COL II (p = 0.0538), COL X (p = 0.2457), SOX 9 (p = 0.7458), or RUNX2 (p = 0.5863) mRNA levels were observed between groups. GAG-production measured in control was approximately 40 µg GAG per microgram DNA. There was no effect of EMD at any concentration on the quantity of GAG production (p = 0.8989; Figure 5B ). Following 35 days of culture in chondrogenic medium, or in the presence of vehicle, or EMD, chondrogenic pellets were stained with safranin O (Figures 6A-E) . Immunohistochemical staining for COL II was also performed on these pellets (Figures 6F-J) . All pellets demonstrated high quantities of GAGs stained by safranin O and collagen type II. However, no differences in staining were observed between pellets in the chondrogenic control conditions or in the presence of different doses of EMD (1, 10, or 100µg/mL).
MSCs IN 3D CULTURE
In order to assess the effects of EMD on the cell distribution and chondrogenic differentiation in a 3D environment, two collagen-GAG scaffolds were seeded with human MSCs and cultured in the presence or absence of TGFβ1 (10 ng/mL) and/or EMD (100 µg/mL). Hematoxylin and eosin staining demonstrated similar cellular distribution in both conditions (Figures 7A-D) . Thionine staining illustrated the presence of GAGs in both conditions (Figures 7E-H) . Upon quantification of the amount of GAG production in two scaffolds per condition, less GAG/DNA was produced in the TGFβ1 + EMD condition (Figure 8) . As this was only performed with cells from one donor, it was not possible to statistically analyze these results.
DISCUSSION
Treatment of large bone defects is challenging. Current treatment options such as autologous bone or bone substitutes are often accompanied by limitations and serious complications, highlighting the necessity for an alternative treatment option to be developed (Arrington et al., 1996; Meijer et al., 2008; Vahabi et al., 2012; Wiggins et al., 2012) . Reports on the ability of EMD to improve MSC osteogenesis are mixed (Narukawa et al., 2007b;  Frontiers in Bioengineering and Biotechnology | Tissue Engineering and Regenerative Medicine Gawlitta et al., 2010; Jue et al., 2010; Qu et al., 2010; Grandin et al., 2012) while little is known about the effects of EMD on chondrogenesis of human MSCs. Bone formation utilizing EO, in which MSCs are chondrogenically differentiated in vitro, and implanted, forming bone in vivo, represents a promising new avenue of research in the field of bone tissue engineering (Gawlitta et al., 2010) . We hypothesized that, given the reported abilities of EMD to improve cell proliferation, migration, and differentiation (particularly osteogenically) (Narukawa et al., 2007a; Jue et al., 2010; Qu et al., 2010; Song et al., 2010) , EMD might also improve the chondrogenic priming of human MSCs. In this study, we focused on chondrogenic differentiation of adult human MSCs as a first step to tissue engineering bone via the process of EO. In order to put the work in the context of prior research, we also assessed osteogenic and adipogenic differentiation of these cells in the presence of EMD.
No differences were observed in GAG production nor in COL II expression in any of the conditions. While the group of Narukawa found an upregulation of COL II, COL X, and SOX 9, as well as increased GAG production following chondrogenic treatment of the ATDC5 hypertrophic cell line in the presence of Emdogain (Narukawa et al., 2007a) , we observed no effects on chrondrogenic differentiation in primary human MSCs. Given the natural tendency of these teratoma derived ATDC5 cells to progress along www.frontiersin.org the chondrogenic lineage toward hypertrophy, it is hard to directly compare the two cell types. The effect of EMD on cell migration and chondrogenesis in a 3D environment, a collagen-GAG scaffold, was also analyzed in this study. This was only performed using cells from a single donor on two scaffolds per condition. On histology, no differences were observed between chondrogenically treated groups. However, while chondrogenisis did occur, there was a trend toward decreased GAG production in the EMD treated samples. This experiment would require repetition with MSCs from several donors to confirm if this is the case.
We observed no effect of EMD at any dose on the ability of cells extracellular matrix production or on the gene level when stimulated osteogenically. This is in agreement with the work of some other groups (van den Dolder et al., 2006; Mrozik et al., 2012) . However, other groups also stated EMD, or components of it, stimulated the differentiation of MSCs toward osteocytes (Keila et al., 2004; Itoh et al., 2006; Narukawa et al., 2007b; Amin et al., 2012; Ramis et al., 2012) . These groups utilized both celllines and rat derived MSCs, as well as only selective proteins found in EMD, which may explain the differences observed. Considering published work and our results, we have no evidence to support the idea that EMD would negatively influence osteogenic differentiation of human MSCs. The in vivo effects of EMD on ossification remain unclear. Some groups reported enhanced bone induction in vivo in both animals and humans (Hammarstrom et al., 1997; Boyan et al., 2000; Jaiswal and Deo, 2013) while others showed no effect of EMD on the formation of mineralized bone (Schneider et al., 2011) . Yagi showed that EMD inhibits RANKL expression, resulting in inhibited osteoclast formation, the cells that are responsible for bone resorption (Yagi et al., 2009) . The variability in these results could be caused by factors such as biological characteristics of the defect and patient variability (Venezia et al., 2004) . However, these results are based on bone formation by surrounding cells instead of implanted chondrogenically primed cells. It is difficult to extrapolate the results observed in this study to the in vivo/clinical situation. We observed a mild trend toward inhibition of adipogenic differentiation at the highest dose of EMD on human MSCs. No tests have been performed to determine the effects of EMD on adipogenic differentiation of MSCs previously. The decreasing trend toward adipogenic differentiation of MSCs, in this proposed application, could be considered a positive outcome suggesting undesirable fat tissue formation is unlikely.
Enamel matrix derivative does not appear to effect the multilineage differentiation of human MSCs. There may be a slight inhibitory effect of EMD, at the highest dose, on adipogenesis. However, this was not proven to be statistically significant. While this work suggests that EMD would not increase the chondrogenic potential of MSCs, which could be utilized in a bone tissue construct via EO for the treatment of large bone defects, there is also no evidence that bone formation would be inhibited if EMD was used in combination with MSCs for the repair of minor bone defects for periodontal tissue repair.
